Dr Mark E Eaton, MD in Annapolis, MD - Medicare Dermatology

Dr Mark E Eaton, MD is a medicare enrolled "Dermatology" physician in Annapolis, Maryland. He went to Mercer University School Of Medicine and graduated in 2000 and has 24 years of diverse experience with area of expertise as Dermatology. He is a member of the group practice Derm Associates Llc and his current practice location is 71 Old Mill Bottom Rd N, Suite 300, Annapolis, Maryland. You can reach out to his office (for appointments etc.) via phone at (410) 268-3887.

Dr Mark E Eaton is licensed to practice in Maryland (license number D0075780) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1629070495.

Contact Information

	Dr Mark E Eaton, MD
	71 Old Mill Bottom Rd N, Suite 300, Annapolis, MD 21409-5410
	(410) 268-3887
	(410) 268-8171

Physician's Profile

Full Name	Dr Mark E Eaton
Gender	Male
Speciality	Dermatology
Experience	24 Years
Location	71 Old Mill Bottom Rd N, Annapolis, Maryland
Accepts Medicare Assignments	Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Dr Mark E Eaton attended and graduated from Mercer University School Of Medicine in 2000

NPI Data:

NPI Number: 1629070495
Provider Enumeration Date: 08/11/2005
Last Update Date: 10/25/2017

Medicare PECOS Information:

PECOS PAC ID: 1759562721
Enrollment ID: I20130529000841

Medical Identifiers

Medical identifiers for Dr Mark E Eaton such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1629070495	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208D00000X	General Practice	0101232096 (Virginia)	Secondary
207N00000X	Dermatology	D0075780 (Maryland)	Primary

Group Practice Association

Group Practice Name	Group PECOS PAC ID	No. of Members
Derm Associates Llc	4688653306	36

News Archive

Osteoporosis study: Protelos have significant bone-forming activity than bisphosphonates

Protelos has significantly greater bone-forming activity than the commonly prescribed bisphosphonate, alendronate, according to results of the largest-ever biopsy study in post-menopausal women presented today at the European Congress on Osteoporosis and Osteoarthritis in Valencia.

Heart docs dismiss bias claims stemming from industry support of meeting

Doctors said the heart society meeting was an important opportunity to learn about new research in their field and see new products on the market. Unlike in many other areas of medicine, they said, electrophysiologists work hand-in-hand with device company representatives to program implantable defibrillators and diagnose problems.

Non-kidney transplant patients likely to undergo kidney transplant prior to dialysis: Study

Kidney failure may accompany or complicate transplantation of the liver, heart, or lung. Because increasing numbers of individuals are receiving non-kidney transplants, researchers have wondered whether more of such patients are being listed for kidney transplants.

Low levels of miR-29 could reduce susceptibility to cardiac fibrosis

Cardiac fibrosis involves an increase of connective tissue in the cardiac muscle, causing a loss of function. A team of researchers at the Technical University of Munich has now discovered that microRNA 29 (miR-29) plays an important role in the formation of tissue fibrosis.

United Therapeutics submits pre-market approval application for use of Remodulin with implantable drug infusion system

United Therapeutics Corporation (NASDAQ: UTHR) announced today that Medtronic, Inc. (NYSE: MDT) has submitted a pre-market approval application to the U.S. Food and Drug Administration (FDA) for the use of Medtronic's SynchroMed® II implantable drug infusion system (including a newly developed catheter) for use with United Therapeutics' Remodulin® (treprostinil) Injection delivered intravenously to patients with pulmonary arterial hypertension.

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Dr Mark E Eaton allows following entities to bill medicare on his behalf.

Entity Name	Derm Associates Llc
Entity Type	Part B Supplier - Clinic/group Practice
Entity Identifiers	NPI Number: 1649271354 PECOS PAC ID: 4688653306 Enrollment ID: O20180702001570

News Archive

Osteoporosis study: Protelos have significant bone-forming activity than bisphosphonates

Heart docs dismiss bias claims stemming from industry support of meeting

Non-kidney transplant patients likely to undergo kidney transplant prior to dialysis: Study

Low levels of miR-29 could reduce susceptibility to cardiac fibrosis

United Therapeutics submits pre-market approval application for use of Remodulin with implantable drug infusion system

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Mark E Eaton is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Mark E Eaton, MD 71 Old Mill Bottom Rd N, Suite 300, Annapolis, MD 21409-5410 Ph: (410) 268-3887	Dr Mark E Eaton, MD 71 Old Mill Bottom Rd N, Suite 300, Annapolis, MD 21409-5410 Ph: (410) 268-3887

News Archive

Osteoporosis study: Protelos have significant bone-forming activity than bisphosphonates

Heart docs dismiss bias claims stemming from industry support of meeting

Non-kidney transplant patients likely to undergo kidney transplant prior to dialysis: Study

Low levels of miR-29 could reduce susceptibility to cardiac fibrosis

United Therapeutics submits pre-market approval application for use of Remodulin with implantable drug infusion system

Dermatology Doctors in Annapolis, MD

Dr. Christine D Ambro, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 71 Old Mill Bottom Rd N, Suite 300, Annapolis, MD 21409 Phone: 410-268-3887 Fax: 410-268-8171
Dr. Gerald W Newman, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 2002 Medical Pkwy, Suite 650, Annapolis, MD 21401 Phone: 410-224-8001 Fax: 410-224-8002
Lisa Renfro, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2002 Medical Pkwy, Suite 630, Annapolis, MD 21401 Phone: 410-224-2260 Fax: 410-224-3090
Kelly Lorraine Mcguigan, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 101 Ridgely Ave, Suite 10, Annapolis, MD 21401 Phone: 410-280-0960 Fax: 410-280-0963
Aaron Fong, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 71 Old Mill Bottom Rd N Ste 300, Annapolis, MD 21409 Phone: 410-268-3887 Fax: 410-268-8171
Dr. Mary F. Farley, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 703 Giddings Ave, Suite 700, Annapolis, MD 21401 Phone: 410-263-5439 Fax: 410-263-7482
Dr. William W Stocker, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 588 Bellerive Rd, Annapolis, MD 21409 Phone: 410-349-3065

Dr Mark E Eaton, MD - Medicare Dermatology in Annapolis, MD

Contact Information

Physician's Profile

Medical Identifiers

Medical Taxonomies and Licenses

Group Practice Association

Osteoporosis study: Protelos have significant bone-forming activity than bisphosphonates

Heart docs dismiss bias claims stemming from industry support of meeting

Non-kidney transplant patients likely to undergo kidney transplant prior to dialysis: Study

Low levels of miR-29 could reduce susceptibility to cardiac fibrosis

United Therapeutics submits pre-market approval application for use of Remodulin with implantable drug infusion system

Medicare Reassignments

Osteoporosis study: Protelos have significant bone-forming activity than bisphosphonates

Heart docs dismiss bias claims stemming from industry support of meeting

Non-kidney transplant patients likely to undergo kidney transplant prior to dialysis: Study

Low levels of miR-29 could reduce susceptibility to cardiac fibrosis

United Therapeutics submits pre-market approval application for use of Remodulin with implantable drug infusion system

Medicare Part D Prescriber Enrollment

Mailing Address and Practice Location

Osteoporosis study: Protelos have significant bone-forming activity than bisphosphonates

Heart docs dismiss bias claims stemming from industry support of meeting

Non-kidney transplant patients likely to undergo kidney transplant prior to dialysis: Study

Low levels of miR-29 could reduce susceptibility to cardiac fibrosis

United Therapeutics submits pre-market approval application for use of Remodulin with implantable drug infusion system

Dermatology Doctors in Annapolis, MD